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Abstract 
A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme 
urokinase-type plasminogen activator (uPA, Ki = 7 M), a promising anticancer target. Several studies 
have demonstrated significant antitumor/metastasis properties for amiloride in animal cancer models 
and it would appear that these arise, at least in part, through inhibition of uPA. Selective optimization 
of amiloride’s structure for more potent inhibition of uPA and loss of diuretic effects would thus appear 
as an attractive strategy towards novel anticancer agents. The following report is a preliminary 
structure-activity exploration of amiloride analogs as inhibitors of uPA. A key finding was that the 
well-studied 5-substituted analogs ethylisopropyl amiloride (EIPA) and hexamethylene amiloride 
(HMA) are approximately 2-fold more potent than amiloride as uPA inhibitors. 
Orally active non-cytotoxic agents capable of inhibiting the progression of primary tumors to 
metastasis have long been a goal in anticancer drug discovery.1 Upregulation of the plasminogen 
activation system (PAS) is known to play a critical role in tumor invasion and metastasis2,3 and several 
components of the PAS offer attractive drug targets in this context.4-6 In its simplest form, the PAS 
comprises the serine protease urokinase-type plasminogen activator (uPA), its cognate 
glycosylphosphatidylinositol (GPI)-anchored cell surface-bound receptor (uPAR) and two endogenous 
serpins; plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2). 
Receptor-bound uPA efficiently cleaves and thus activates co-localised plasminogen at the cell surface, 
which reveals the broad spectrum serine protease plasmin. Plasmin activates downstream extracellular 
proteases (e.g. matrix metalloproteases) and latent growth factors and together these lead to pericellular 
proteolysis and remodelling of the local extracellular environment – key events required for metastasis 
(reviewed in Refs 7 and 8). To highlight the importance of the PAS in metastasis, upregulated uPA and 
PAI-1 have been shown to be the strongest known prognostic biomarkers of shortened disease-free 
survival and overall survival in breast cancer and the most accurate predictors of metastasis in lymph-
node-negative tumours.9 
 
One approach towards dampening PAS activity and potentially inhibiting metastasis is to target the serine 
protease activity of uPA. Several classes of uPA inhibitors have been reported and selected analogs have 
undergone preclinical evaluation as non-cytotoxic antitumor/metastasis agents.10 An orally active uPA inhibitor 
prodrug MESUPRON® (Wilex AG, Germany) is currently undergoing two phase II trials for the 
treatment of breast and pancreatic tumors.11 A general problem with uPA inhibitors, however, is that 
many contain highly basic amidines or guanidines which often confer poor drug-like properties.12 
These positively charged groups are necessary for making a key salt-bridge contact with Asp189 
located at the base of uPA’s S1-pocket. Scaffolds which could employ less basic groups to make this 
crucial interaction are thus sought after for elaboration into uPA inhibitors with improved properties. 
 
Amiloride.HCl 1 is an orally administered potassium-sparing diuretic that has been used clinically for 
several decades, most commonly in combination with thiazide (e.g. hydrochlorothiazide) or loop 
diuretics (e.g. frusemide) as an antikaliuretic.13 Studies have shown that amiloride is also a moderately 
potent competitive inhibitor of uPA (Ki = 7 M)14 and that uPA inhibition correlates with significant 
antitumor/metastasis effects of the compound in vivo.15 The published X-ray co-crystal structure of 
amiloride bound to uPA16 (Figure 1) reveals that the drug positions its acylguanidine unit deep within 
the S1 pocket to make the key salt-bridge interaction with Asp189. The low M uPA inhibitory 
potency of amiloride combined with its demonstrated antitumor/metastasis effects in animal models, 
the reduced basicity of its acylguanidine (pKa = 8.8),
17 its longstanding use as a safe oral K+-sparing 
diuretic and its known selectivity for uPA over closely related off-target serine proteases (i.e. tissue-
type plasminogen activator (tPA), plasmin, thrombin and kallikrein)14 suggest it is an excellent starting 
point for a selective optimisation of side-activity (SOSA)18 study aimed at producing a more potent, 
orally active uPA inhibitor for use in the cancer setting. The following report is a preliminary structure-
activity exploration of amiloride analogs as inhibitors of uPA. 
 
The reported amiloride:uPA X-ray structure showed that amiloride occupies the S1 and S1 sites of 
uPA by making a network of hydrogen bonds and van der Waals contacts in addition to the salt-bridge 
interaction with Asp189 (Figure 1).16 The Ser190 hydroxyl group forms a hydrogen bond to a terminal 
nitrogen atom of the acylguanidine, which in turn forms a hydrogen bond with a water molecule bound 
deep within the S1 pocket. The Ser190 hydroxyl also forms a hydrogen bond to this water molecule, as 
does the acylguanidine carbonyl oxygen. The Gly219 carbonyl oxygen forms a weak hydrogen bond 
(O---N distance 3.3 Å) to the acylguanidine amide NH. The Ser195 hydroxyl group is hydrogen 
bonded to the amino group at C3, while the amino group at C5 forms a hydrogen bond to an 
adventitious sulfate ion bound in the oxyanion hole. The sulfate ion is further held in place by hydrogen 
bonds to the Ser195 hydroxyl, His57 imidazole nitrogen and Gly193 amide NH. The chlorine atom at 
C6 partially occupies the S1 subsite and participates in interactions with residues Gln192, Gly216, 
Gly219 and the Cys191-Cys220 disulfide bond. 
 
 
Figure 1. (a) X-ray crystal structure of the amiloride 1:uPA complex (binding site only); PDB 1f5l.16 
(b) Summary of the binding interactions between amiloride (blue), uPA (black), an adventitious sulfate 
of crystallization (red) bound in the oxyanion hole and a water molecule (green) bound deep within the 
S1 pocket. 
 
The structural features of amiloride that were examined in this study are summarised in Figure 2. All 
compounds were purified by preparative rp-HPLC to greater than 95% purity (analytical rp-HPLC) and 
evaluated for uPA inhibitory potency using a 96-well plate in vitro enzyme assay. The commercially 
available colorimetric uPA substrate Spectrozyme UK (American Diagnostica Inc.) was used with 
active high molecular weight uPA (HMW-uPA) in all assays. Briefly, compounds were dissolved in 
DMSO to create 20 mM stock solutions which were diluted with buffer in series in the plates to give 
final DMSO concentrations of less than 2%. Two compounds were assayed per plate with triplicate 
measurements taken for each inhibitor concentration. Assay blanks (no enzyme) were included to 
account for the colour of some inhibitors. Amiloride was included in all assays as a positive control 
(IC50 = 11 M under the assay conditions). Plates were incubated at 37 oC in a plate reader and 
absorbances read at 405 nm over time. Absorbance values were recorded for a time point taken from 
the linear region of plots of absorbance vs time and IC50 values were calculated from sigmoidal dose 
response curves of absorbance vs log[inhibitor] using GraphPad Prism V. 5.01 software. 
 
 
Figure 2. Summary of the amiloride structural features examined. 
 
At the outset we were interested in establishing the importance of the acylguanidine:Asp189 interaction 
and, specifically, whether this interaction might be providing the bulk of amiloride’s uPA affinity with 
other contacts perhaps playing only a minor role. A series of aroylguanidines 2-8 with varied aryl cores 
were thus synthesized by refluxing their commercially available methyl ester precursors with 
guanidine.HCl (pre-neutralised with Na in iPrOH) in isopropanol. Methyl esters which were not 
commercially available were synthesised by methylation of their available carboxylic acids by using 
CH3I/Cs2CO3 in N,N-dimethylformamide (DMF). As shown in Table 1, the aroylguanidines were all 
essentially inactive with IC50 values above 1 mM (except 7, IC50 = 222 M). It was significant that 2-
pyrazinoyl guanidine 5 was inactive as this structure forms the core of amiloride. These findings are 
evidence that the 2-pyrazinoyl guanidine core of amiloride is not on its own responsible for uPA 
affinity and that the 3- and 5-amino and 6-chloro groups, in combination with the acylguanidine, 
contribute significantly to binding. The improved potency of the substituted benzoylguanidine 7 (which 
bears an aryl ring substitution pattern similar to amiloride) relative to benzoylguanidine 2 supports this 
conclusion. 
Table 1. Aroylguanidines with varied aryl cores. 
 
 
The importance of the acylguanidine unit was further explored with analogs 9 and 10, which 
incorporate 3-amino-1,2,4-oxadiazole and acylhydrazide isosteric replacements for the acylguanidine, 
respectively. Compound 9 was accessed in 39% yield by refluxing hydroxyguanidine hemisulfate19 and 
sodium in ethanol with the commercially available methyl ester 11.20 Compound 10 was prepared in 
81% yield by refluxing 11 with hydrazine hydrate in ethanol. Analogs 9 and 10 were both found to be 
inactive (IC50 >1000 M) (Scheme 1). 
 
 
Scheme 1. Analogs incorporating acylguanidine isosteres. 
 
The importance of the amino groups at the 5- and 3-positions of amiloride were investigated next with 
the deaminated analogs 12 and 13 (Scheme 2). Chlorination of the commercially available pyrazine 
methyl ester 14 by heating with N-chlorosuccinimide (NCS) in DMF at 80 oC gave 15 in 72% yield. 
Guanidinylation of 15 using the aforementioned conditions provided 12 in 87% yield. Guanidinylation 
of the commercially available methyl ester 16 afforded compound 13 (28%). The chloro analogue of 16 
was not commercially available so the direct 3-deamino analogue of amiloride (i.e. 6-chloro-13) was 
not pursued; however it was later noted that substitution of the 6-chloro group of amiloride 1 with 
bromide (i.e. 6-Br-amiloride 58, Table 3) resulted in a 2-fold increase in activity. This suggests that 6-
chloro 13 would most likely show very similar or only slightly increased activity relative to 13. 
 
It was found that removal of either 3- or 5-amino groups resulted in a total loss of activity (IC50 >1000 
M). Loss of activity upon removing the amino group at C3 (i.e. 13) may (partially) result from losing 
the hydrogen bond between this amine and the OH group of the catalytic Ser195 residue (Figure 1 (b)). 
Explaining the total loss of potency after removing the 5-amino group (i.e. 12) is difficult since this 
group appears not to form any direct contacts with the enzyme, although it does form a hydrogen bond 
with the adventitious sulfate of crystallization bound in the oxyanion hole (Figure 1(b)). 
 
 
Scheme 2. Analogs with 3- and 5-amino groups removed. 
 
A major part of the study focused on amiloride analogs carrying substituents at C5. This was due to 
their ease of synthesis and because many 5-substituted analogs are known which show reduced diuretic 
effects relative to amiloride.21 Application of the SOSA approach to identify amiloride analogs with 
high uPA inhibitory potency for use as antitumor/metastasis agents would (ideally) require that the 
evolved compounds show reduced diuretic activity and minimal effects on K+-levels. While many 
amiloride analogs bearing hydroxyl, alkoxy, mercapto, alkylmercapto, alkyl, aryl and other substituents 
at the 5-position are reported,21, 22  we chose to examine those carrying substituted amines at this 
position after the 5-deaminated derivative 12 was found to be inactive. 
 
The amiloride:uPA X-ray co-crystal structure suggests that substituted amines at C5 should extend 
away from the pyrazine ring towards the oxyanion hole being occupied in the structure by the 
adventitious sulfate ion (Figure 1).16 Analogs incorporating negatively charged groups attached to the 
amine via 1- or 2-carbon linkers (i.e. carboxylates 18 and 20, sulfonate 21, phosphonates 23, 25, 26 and 
tetrazoles 29 and 31) were thus explored under the hypothesis that these groups could potentially 
mimic the sulfate ion and pick up favourable contacts within the oxyanion hole. Uncharged synthetic 
precursors of these inhibitors (carboxylate esters 17 and 19, diethylphosphonates 22 and 24 and nitriles 
28 and 30, respectively) were also examined. Other 5-substituted analogs (27, 32-47) were chosen in 
order to explore a cross-section of inhibitors containing aromatic rings, basic (or quaternary) amines 
capable of carrying positive charges, and compounds containing sulfur. 
 
Nucleophilic aromatic substitution reactions of the 5,6-dichloropyrazinoyl guanidine 49 with requisite 
amines were used to prepare all 5-substituted analogs (Table 2). 49 was obtained in 84% yield from the 
commercially available methyl-5,6-dichloropyrazine carboxylate 48 by guanidinylation using the 
conditions described above. 
 
 
 
Table 2. Analogs with substituted amines at C5. 
 
Amines used in the synthesis of 17, 19, 21, 22, 24, 28, 30, 32-39, 41, 43, 45-47 were all commercially 
available while others required synthesis. Diethyl phosphorohydrazidate 50, 2-(benzyl-methylamino) 
ethylamine 51 and 1-(2-aminoethyl)pyridinium bromide 52 (used in the synthesis of 27, 40 and 42, 
respectively) were prepared by reported methods (Scheme 3).23-25 Tetrazolylalkylamines 53 and 54 
(used in the synthesis of 29 and 31, respectively) were prepared from commercially available alkyl 
chlorides by substitution with ammonia (i.e. 53) or by conversion to the azide followed by Staudinger 
reduction with PPh3 (i.e. 54) (Scheme 3). 
 
 
Scheme 3. Synthesis of non-commercially available amines 50-54.23-25 
 
Esters 17 and 19 were hydrolysed under basic conditions (K2CO3/MeOH/H2O) to yield the carboxylic 
acids 18 and 20, respectively. Phosphonate esters 22 and 24 were fully or partially hydrolysed using 
trimethylsilyl chloride to afford 23, 25 and 26. Oxidation of thioether 43 with Oxone yielded sulfone 
44. An attempt to produce 5-(N,N’-dimethylethane-1,2-diamino)-amiloride by reaction of 49 with 
N,N’-dimethylethylenediamine instead resulted in formation of a novel bicycle 39, where the free 
secondary amine of the initial 5-sustituted product had cyclised onto the 6-position by displacing the 
chloride. 
 
The hypothesis that negatively charged groups appended at C5 might increase potency by acting as 
sulfate mimetics able to make favourable contacts in the oxyanion hole was found to be incorrect. All 
inhibitors bearing C5-substituents capable of carrying negative charges (i.e. 18, 20, 21, 23, 25, 26, 29, 
31) showed dramatically reduced or total loss of activity relative to amiloride, while uncharged 
synthetic precursors of these inhibitors (i.e. 17, 19, 22, 24, 28 and 30) universally showed less dramatic 
losses in potency (IC50 = 25-50 M). Only diethylphosphorohydrazidate 27 (IC50 = 10 M) retained the 
potency of amiloride. Benzylic extensions (compounds 32-36) were well tolerated and produced slight 
(up to 2-fold) increases in potency (p-fluorobenzyl 36, IC50 = 6 M). Of the three analogs substituted 
with benzyl pyridines (compounds 33-35) only the para-substituted pyridine 35 (IC50 = 6 M) showed 
increased potency relative to amiloride. Extension of the benzylamine substituent to phenylethylamine 
caused a 2-fold drop in potency (37, IC50 = 16 M vs 32, IC50 = 8 M).  
 
5-substituted analogs containing 2o, 3o or 4o nitrogens were investigated to examine the effects of 
positively charged groups in this region. Analogs 26 (IC50 = 14 M) and 40 (IC50 = 15 M) bearing 3o 
amino groups showed only slightly reduced potency, while 42 (pyridinium, IC50 = 30 M) and 41 (2o 
amine, IC50 = 28 M) were ~3-fold less potent than amiloride. It was concluded that positive charges in 
C5 substituents do not confer increased potency but they are largely tolerated or produce only minor 
losses in potency. 
 
Analogs 43, 44 and 45, which included sulfur in the C5-substituent, were examined because some 
potent uPA inhibitors have been shown to position sulfonamides in the oxyanion hole.26, 27 The sulfone 
44 (IC50 = 15 M) was found to be slightly more potent than its corresponding sulfide 43 (IC50 = 21 
M), while both compounds were slightly less potent than amiloride. Sulfonamide 45 (IC50 = 35 M) 
was more than 3-fold less potent than amiloride. 
 
The overall trend with this series indicated that analogs bearing shorter amines at C5 tended to slightly 
improve inhibitor potency while the more extended amines produced no improvement or a reduction in 
potency. Inspection of the amiloride:uPA X-ray co-crystal structure (Figure 1) suggests that C5-
substituted analogs should place the substituent near the oxyanion hole, with longer substituents 
extending out further, probably towards solvent. The finding that only slight increases (up to 2-fold) 
and relatively minor reductions (except for the negatively charged analogs) in potency were observed 
with this diverse set of analogs suggests that only non-specific contacts are being made between the 
C5-substituents and the enzyme. The relatively flat SAR trend would be compatible with these 
substituents significantly interacting with the surrounding solvent. 
 
Compounds 46 (commonly known as ethylisopropyl amiloride, EIPA) and 47 (hexamethylene 
amiloride, HMA) were of considerable interest in this study because they are two of the most potent 
known inhibitors of the sodium hydrogen exchanger 1 (NHE1), another emerging antitumor/metastasis 
drug target.28 Amiloride is also a moderately potent NHE1 inhibitor (K0.5 = 7 M) but EIPA 46 and HMA 
47 are 140 x and 524 x more potent, respectively.17, 29 The likelihood that the antitumor/metastasis effects of 
amiloride (and analogs) in vivo arises through dual inhibition of both NHE1 and uPA was recently reviewed,15 
and it was noted there that the inhibitory potencies of EIPA and HMA against uPA had not yet been 
reported. Compounds 46 (IC50 = 6 M) and 47 (IC50 = 6 M) are now shown to be equipotent uPA 
inhibitors and ~2-fold more potent than amiloride. 
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Scheme 4. Synthesis of analogs with variations at C6. 
 
The amiloride:uPA X-ray structure (Figure 1) indicates that the C6 chloro group of amiloride projects 
toward and partially occupies the S1 site.16 A selection of 6-substitued amiloride analogs which either 
remove or replace the chloro group were thus prepared to explore structure-activity relationships about 
the S1 site. Hydrodehalogenation (H2, Pd/C,MgO)21 of amiloride 1 and methyl ester 11 provided 
dechlorinated compounds 55 (59%) and 56 (98%), respectively. Reaction of 55 with N-
iodosuccinimide (NIS) and N-bromosuccinimide (NBS) yielded aryl halides 57 (72%) and 58 (81%), 
and iodination of 56 provided the aryl iodide 59 in 98% yield (Scheme 4). Compounds 60 and 61 were 
produced by hydrodehalogenation (H2, Pd/C,MgO) of 32 and 37 in 78% and 81% yields, respectively. 
Stille and Sonogashira couplings were carried out on iodide 59 with phenyltributylstannane and 
phenylacetylene. Guanidinylation of the resultant esters afforded the 6-substituted analogs 62 and 63 
(71% and 46% yields over two steps, respectively). 
 
Table 3. IC50 values of analogs with variations at C6. 
 
 
Compounds 55, 60 and 61 (i.e. dechloro analogs of 1, 32 and 37, respectively) were used to explore the 
contribution of the chloro group to potency. The three dechloro compounds all showed reduced 
potency (~2-7.5 fold) compared to their 6-chloro variants (Table 3), confirming the favourable 
interaction of the chloro group with the S1 site. The effect of larger halogens at the 6-position was 
also investigated. Relative to amiloride, iodide 57 and bromide 58 produced 5- and 2-fold 
improvements in potency, respectively, suggesting that the larger halogens interact more favourably 
with the S1 site. Previous uPA:inhibitor co-crystal structures showing that the S1 site can 
accommodate an aryl ring12 led us to explore amiloride analogs 62 and 63 carrying phenyl and 
phenylacetylenyl substituents at C6. The two compounds were found to have equal (62 IC50 = 10 M) 
or higher potency (63 IC50 = 2 M) relative to amiloride. 
 
Amiloride shows significant antitumor/metastasis effects in in vivo animal models and it would appear 
that that these probably arise from dual inhibition of uPA and NHE1.15 The in vitro potency of 
amiloride against these two targets is relatively modest, however, so it is conceivable that an analog 
optimised for higher potency against both targets might yield a superior anticancer compound. 
Deliberately optimising compounds to potently interact with two or more independent targets (i.e. 
polypharmacology) is increasing being recognised as a viable drug development strategy.30 The NHE1 
inhibitory potency of many amiloride analogs has been reported and some show greatly increased 
potency relative to amiloride, including the well studied compounds EIPA 46 and HMA 47. In order to 
advance our long-term goal of identifying potent dual NHE1/uPA inhibitors it is necessary to 
characterise the potency of amiloride analogs as uPA inhibitors. 
 
This study initially explored simplified aroylguanidines and analogs containing acylguanidine isosteres. 
It was found that simple aroylguanidines are poor uPA inhibitors and should not be pursued further as 
alternative uPA inhibitor scaffolds. Analogs bearing acylguanidine isosteres were found to be totally 
inactive indicating that the acylguanidine group should be retained. Analogs lacking either the 3- or 5-
amino substituent were used to establish the importance of these groups for inhibitor binding. Both 
compounds were found to be inactive. 
 
It was postulated that analogs incorporating a negatively charged sulfate mimetic at C5 could pick up 
favourable contacts in the oxyanion hole of uPA. Surprisingly, analogs bearing negatively-charged 
groups all showed greatly reduced potency relative to amiloride. Ironically, the uncharged synthetic 
precursors of these compounds all showed much lower reductions in potency. Investigation of alkylaryl 
extensions at C5 were more fruitful, with several analogs showing slightly improved potency. Overall, 
substituted amines at C5 were generally well tolerated with inhibitors being as potent or only slightly 
less potent than amiloride. While exploration of these analogs did not yield an inhibitor with nanomolar 
potency as hoped, it succeeded in showing that substituted amines at the 5-position are at least well 
tolerated. Amiloride analogs substituted at the 5-position are known to show reduced diuretic effects.21 
If a high potency uPA inhibitor can eventually be evolved from amiloride it will be useful to know that 
the 5-position can be varied to reduce diuretic effects and to modulate physiochemical properties 
without dramatically altering uPA affinity. 
 
Removal of the 6-chloro group was investigated with dechloro analogs; 55, 60 and 61. When 
compared with their 6-chloro counterparts, the three dechloro compounds each showed significantly 
reduced potency indicating that placing a group into the S1 pocket is important. Other analogs 
substituted at the 6-position with larger halogens (i.e. 57, 58) and aryl groups (i.e. 62, 63) showed 
improved potency, with 57 and 63 being the most potent compounds identified in the study (~6-fold 
increase in potency relative to amiloride).  
 
Determining the uPA inhibitory potency of 46 and 47 was of particular interest since these compounds 
are two of the most potent NHE1 inhibitors known.17, 29 The two compounds were shown in the current 
work to provide 2-fold improvements in potency relative to amiloride. While not large increases in 
potency the result confirms that 5-substituted amiloride analogs with very high potency against NHE1 
are able to maintain potency against uPA (relative to the unsubstituted amiloride) – an important 
finding in the search for dual uPA/NHE1 inhibitors. It also supports that the demonstrated 
antitumor/metastasis effects of 46 and 47 most likely arise through dual inhibition of uPA and NHE1. 
 
Analogs of 46 and 47 that retain the respective ethylisopropyl and hexamethylene amines at C5 while 
replacing the 6-chloro group with substituents that are able to make more favourable contacts in the 
S1 site may lead to more potent uPA inhibitors that retain potency against NHE1. It is worth noting 
that 6-Iodo-46 and 6-Bromo-47 are 313- and 566-fold more potent NHE1 inhibitors than amiloride, 
respectively, and 1.40- and 1.08-fold higher in potency than their 6-chloro counterparts 46 and 47.17 
The current study has shown that converting amiloride to the 6-Bromo or 6-Iodo derivatives enhances 
uPA inhibition. The compounds 6-Iodo-46, 6-Bromo-47 and derivatives of 46 and 47 that carry other 
C6-substituents are currently being examined in these laboratories in pursuit of dual uPA/NHE1 
inhibitors. 
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